Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
2024年4月11日 - 9:00PM
ビジネスワイヤ(英語)
Powered by digital pathology and AI algorithms,
Patholytix Foresight drives speed and quality in toxicologic
pathology practices
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced the launch of Patholytix Foresight, a non-clinical
artificial intelligence (AI) decision support tool developed in
collaboration with Deciphex, an innovator in pathology AI. By
combining Deciphex’s unique digital pathology solutions with
Charles River’s robust non-clinical pathology programs, clients of
both organizations will have access to the technology-driven
capabilities to accelerate primary evaluation and peer review in
toxicologic pathology assessment, enhancing decision-making in drug
discovery and safety assessment.
In experimental and toxicologic pathology in particular,
traditional light microscopic pathology methods can fall short of
maintaining consistency and efficiency in analyzing histopathology
data. By augmenting evaluations with decision support technology,
toxicologic pathologists have access to simple, visual tools to
facilitate efficiency, consistency, and accuracy in their work.
Developed through a research collaboration between Charles River
and Deciphex, Patholytix Foresight incorporates organ-based lesion
classifiers created from an extensive data warehouse. Built on
Patholytix 4.0, Deciphex's flagship non-clinical workflow, the tool
integrates these AI classifiers with Whole Slide Images (WSI) to
enhance and accelerate a pathologist’s decision-making by
streamlining workflows for identifying critical features in
specific tissues.
Approved Quotes
- “AI-powered solutions are accelerating the pace and efficiency
of drug development, and the launch of Patholytix Foresight marks a
significant milestone in our collaborative efforts to enhance the
digital transformation of toxicological pathology.” – Professor
Julie Frearson, PhD, Corporate Senior Vice President, Chief
Scientific Officer, Charles River
- “In collaboration with Charles River Laboratories, we look
forward to bringing Patholytix Foresight to the forefront of
digital pathology, empowering pathologists worldwide with
cutting-edge AI technology for more efficient and accurate
toxicological assessments. This advance is part of our collective
vision to enable AI-empowered and regulated digital primary review
of safety studies.” – Pierre Moulin, MD, PhD, MBA, Chief Scientific
Officer, Deciphex
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
About Deciphex Deciphex is a pioneering company at the
forefront of the digital transformation of pathology. By networking
with global pathologists and leveraging AI-driven solutions,
Deciphex accelerates certainty in pathology reporting, ultimately
enhancing patient care and advancing drug development. With a
diverse and experienced team and cutting-edge platforms like
Diagnexia and Patholytix, Deciphex is set to redefine the future of
pathology. For more information, visit www.deciphex.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240411845549/en/
Investor Contact: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media Contact: Amy Cianciaruso Corporate Vice President,
Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
過去 株価チャート
から 5 2024 まで 6 2024
Charles River Laboratories (NYSE:CRL)
過去 株価チャート
から 6 2023 まで 6 2024